ClinicalTrials.gg
RecruitingNCT07198581ALLIANCEUpdated Apr 22, 2026

AI-Assisted Chemotherapy Side Effect Management

An interventional study of LLM-assisted chemotherapy side effect management in Breast Cancer and Colorectal Cancer, sponsored by Incheon St.Mary's Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Incheon St.Mary's Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.

Planned enrollment
291st of 505
174 · median 218
Started
2025
with 38 others
No phase
90 of 618
26 open now
Primary completion
2026-10
later than 92 of 229 live
Registered
590th of 618
by date

Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 291st largest by planned enrollment of the 505 interventional ones that give a count, is one of 39 that started in 2025, is one of 90 with no phase, reaches primary completion later than 92 of the 229 other live ones, and was the 590th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

126 more — sign in →

All 132 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 618 studies in Breast Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors. Adults with histologically confirmed breast or colorectal cancer scheduled for at least 3 months of systemic chemotherapy will be randomly assigned (1:1) to receive either LLM-assisted care or standard care.

The study employs an adaptive design with initial enrollment of 60 patients (30 per arm), followed by interim analysis. Unless enrollment is stopped for safety reasons identified at interim analysis, an additional 114 patients will be enrolled for a maximum total of 174 patients (87 per arm).

In the intervention group, healthcare providers input anonymized patient symptom data into an LLM system using sessions where data is not retained, which generates evidence-based management recommendations. Physicians critically review these recommendations and use them as reference for clinical decision-making, with final treatment decisions remaining under physician discretion. The control group receives standard supportive care without LLM assistance.

The primary outcome is change in health-related quality of life measured by EORTC QLQ-C30 global health status/QoL scale from baseline to end of treatment. Secondary outcomes include proportion achieving clinically meaningful improvement (≥8-point increase), treatment adherence, dose intensity, healthcare resource utilization, and physician acceptance of LLM recommendations.

Read the detailed description

Chemotherapy-induced side effects affect patient quality of life and treatment outcomes. Studies indicate 86% of patients receiving chemotherapy experience at least one side effect, with 30% reporting moderate to severe symptoms. Common adverse effects including nausea, vomiting, fatigue, anorexia, pain, diarrhea, constipation, mucositis, and peripheral neuropathy lead to dose reductions, treatment delays, or discontinuation.

Care gaps persist despite advances in supportive care due to clinician time constraints and variable attention to specific side effects. Digital health interventions have demonstrated improved quality of life, reduced emergency department visits, and enhanced survival in cancer patients. A 2025 umbrella review reported positive effects of digital health interventions on multiple mental health indicators in cancer patients.

LLMs offer natural language processing and medical knowledge bases. Clinical application remains limited, with only 5% of LLM healthcare studies involving actual patient care according to recent systematic reviews. Reliability concerns and hallucination require physician oversight. While healthcare providers manage life-threatening chemotherapy toxicities effectively, less attention may be given to symptoms that impact quality of life without immediate life-threatening consequences.

This adaptive randomized controlled trial employs a two-stage design. Stage 1 enrolls 60 patients (30 per arm) with breast or colorectal cancer without malignancy-related symptoms at baseline. Stratification occurs by cancer type. The intervention involves healthcare providers collecting patient symptoms during clinic visits, excluding information that could identify patients, anonymizing information according to standardized prompts, and inputting data into the LLM system via temporary chat sessions where no records are retained. The LLM generates symptom analysis and management recommendations. Physicians review recommendations and adjust treatment plans accordingly, with all final decisions remaining under physician responsibility.

Interim analysis after 60 patients are enrolled evaluates safety, feasibility, and efficacy. Safety assessment includes stopping for serious LLM-related issues. Interim analysis after 60 patients are enrolled evaluates safety and feasibility. Safety assessment includes stopping for serious LLM-related adverse events. Feasibility assessment examines LLM system usage rate and physician satisfaction. No formal efficacy stopping rule is applied; therefore, no alpha adjustment is required for the final analysis. Based on interim results, up to 114 additional patients may be enrolled for a maximum total of 174 participants.

The primary analysis uses linear mixed-effects models adjusting for baseline scores and stratification factors. A clinically meaningful difference of 8 points on the EORTC QLQ-C30 scale with standard deviation of 20 points provides >85% power at the final sample size. Secondary analyses include logistic regression for clinically meaningful improvement rates, appropriate statistical tests for adherence and toxicity outcomes, and Poisson/negative binomial regression for healthcare utilization.

This study aims to evaluate whether LLM-assisted intervention improves patient outcomes and healthcare resource utilization in oncology practice, providing evidence for the clinical application of LLMs as decision support tools in patient care.

03

Conditions studied

  • Breast Cancer
  • Colorectal Cancer

Keywords

  • Large Language Model
  • LLM
  • Breast cancer
  • Side effect
  • Supportive care
  • colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years old) diagnosed with confirmed solid (breast cancer, colorectal cancer)
  • Patients scheduled to receive at least 3 months of systemic chemotherapy
  • performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric disorders
  • Cognitive impairment affecting ability to report symptoms
  • Presence of cancer-related symptoms prior to chemotherapy initiation
  • Concurrent participation in trials evaluating other symptom management interventions Inability to provide less than 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    LLM Intervention Group

    Patients receive standard chemotherapy with AI-assisted symptom management. Healthcare providers input anonymized patient symptoms into a large language model system during clinic visits. The LLM generates management recommendations that physicians review and consider for treatment decisions.

    Behavioral: LLM-assisted chemotherapy side effect management

  • No intervention
    Standard Care Group

    Patients receive standard chemotherapy with conventional symptom management based on institutional protocols and physician clinical judgment.

Interventions

  • BehavioralLLM-assisted chemotherapy side effect management

    Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM system via temporary chat sessions. The LLM generates management recommendations which physicians review and consider when adjusting treatment plans. Healthcare providers anonymize patient information and input into LLM using temporary chat sessions. LLM recommendations serve as reference only, with physicians making all final clinical decisions.

06

What researchers measure

Primary outcomes

  1. Change in health-related quality of life measured by EORTC QLQ-C30 global health status/QoL scale (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 - Global Health Status/Quality of Life Scale)

    Change in health-related quality of life measured by EORTC QLQ-C30 global health status/QoL scale (range 0-100, higher scores indicate better outcomes; less decline indicates better outcomes)

    Time frame: Baseline, mid-treatment, end of treatment, 3 months post-treatment (up to 9 months)

Secondary outcomes

  1. Proportion of patients with ≥8 points improvement in EORTC QLQ-C30 global health status/QoL scale

    Time frame: Baseline, mid-treatment, end of treatment, 3 months post-treatment (up to 9 months)

  2. Proportion of patients completing all planned chemotherapy cycles

    Time frame: Throughout chemotherapy treatment period (approximately 3-6 months)

  3. Relative dose intensity (percentage of planned dose actually administered)

    Time frame: Throughout chemotherapy treatment period (approximately 3-6 months)

  4. Frequency of grade 3-4 toxicities according to CTCAE v5.0

    Time frame: Throughout chemotherapy treatment period (approximately 3-6 months)

  5. Number of emergency department visits and unplanned hospitalizations

    Time frame: From baseline through 3 months after treatment completion (up to 9 months)

  6. Physician survey with LLM recommendations (intervention arm only)

    Mean physician usefulness score for LLM recommendations assessed by physician evaluation survey (1-5 point scale) (intervention arm only)

    Time frame: Monthly during treatment and at end of treatment, up to 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 11 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 30, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07198581
Lead sponsor
Incheon St.Mary's Hospital
Responsible party
Young-Joon Kang (Assistant Professor, Incheon St.Mary's Hospital) — Principal investigator
First posted
Sep 30, 2025
Start date
Nov 12, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Apr 22, 2026

Study contacts

Young-Joon Kang
Contact
yjkang.md@gmail.com
+82322805179

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion